Prefer to view this content on our website? Click here.
Trade SpaceX Now Without Trading SpaceX
The most tempting trades are often the ones that can't actually be made.
SpaceX remains private, which means there's no ticker, no options chain, and no direct public-market access. Yet the speculation cycle is real. Recent reporting has suggested SpaceX could pursue a blockbuster 2026 IPO that might raise more than $25 billion.
That kind of headline can do two things at once:
-
Pull investor attention toward "the next big listing."
-
Heat up the broader IPO ecosystem—from underwriting chatter to "risk-on" sentiment around newly public growth names.
Here's the problem: even when a coveted IPO finally arrives, buying it on day one can feel like flipping a coin.
Why IPOs are a coin flip
IPOs are not "normal" trading events. They're supply-and-demand events mixed with narrative, scarcity, and positioning.
A new listing can:
-
Surge on debut and keep running (the dream scenario)
-
Pop and fade as early buyers rush to monetize momentum
-
Whipsaw violently as the market tries to discover a realistic valuation
Ferrari is a useful reminder that hype and pricing dynamics don't always translate into a smooth ride. Ferrari priced its IPO at $52 per share and began trading on the NYSE under "RACE" in October 2015. Early trading saw an initial jump near $60, reflecting strong demand and oversubscription narratives. But even in cases where an IPO debuts strong, the post-IPO phase can still be volatile as liquidity builds, fundamentals reassert themselves, and lockups expire.
That's why one of the best ways to "invest in an IPO" can be… not investing in any single IPO at all.
Sponsored by Immersed
The Next Phase of AI Is Not About Chat
#1 work app on the Meta Quest Store.
Samsung headset's launch partner.
Intel's former CEO invested.
The first wave of AI lived on text and prompts.
The next wave operates in real environments.
This short video explains how an under-the-radar company, already used by 1.5 million professionals, is applying AI to real work informed by how people actually move, focus, and interact throughout the day.
Pre-IPO investors can still access shares for $0.66 each, before a potential IPO.
Invest Before the Pre-IPO Round Closes
*DISCLOSURE: This is a paid advertisement for Immersed Reg A+ offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks immersed.com
The SpaceX angle: the trade may be the IPO cycle, not the IPO
If SpaceX does move toward a 2026 listing, the largest near-term market impact may not be limited to SpaceX. Mega-IPO speculation tends to lift the entire conversation around:
In other words, the practical trade can be exposure to the basket of newly public companies—rather than trying to nail the perfect entry on one headline-driven debut.
That's where IPO-focused ETFs come in.
Option #1: Own the "newly public leaders" basket
ETF: First Trust US Equity Opportunities ETF (SYM: FPX)
A rules-based basket of large U.S. IPOs
FPX is built around the idea that some of the most powerful moves in a company's public-market life can occur after the initial debut—once liquidity improves and institutions begin building positions. The ETF is commonly described as tracking the IPOX-100 U.S. Index and providing exposure to a portfolio of large U.S. companies in their post-IPO window.
The cost structure matters with thematic ETFs, FPX's expense ratio is listed at 0.61%.
Why FPX can work as a "SpaceX-adjacent" idea
-
Diversification across IPO outcomes: One flop doesn't sink the thesis.
-
Participation in the broader IPO environment: If issuance and risk appetite rise, the basket can benefit.
-
Rules-based exposure: Less dependence on discretionary stock picking.
Risks to respect
-
IPO cycles are feast-or-famine: When issuance dries up, the theme can stall.
-
Sector concentration risk: IPO waves can be heavily skewed to tech or a single style factor.
-
Valuation risk: Newly public companies can be priced aggressively in hot markets.
Med-X Inc.
Med-X is gearing up for a possible NASDAQ listing (ticker: MXRX). But the real opportunity is now – before public health adoption accelerates.
In certain use cases, Med-X's all-natural pesticides have outperformed chemical brands in independent lab tests, delivering safer solutions without sacrificing results.
Now, Med-X is approaching a major real-world validation catalyst: Florida Mosquito Control Districts are independently testing Nature-Cide as an adulticide, larvicide, and barrier treatment – with the goal of adding it to their official rotation.
Florida has the most well-funded mosquito control districts in the United States and carries the highest responsibility for controlling mosquito-borne threats. These districts are known as leaders and innovators in Integrated Mosquito Management – meaning that when Florida adopts a solution, other regions often follow.
And right now, these districts need better options.
Public scrutiny over the chemical pesticides traditionally used in mosquito control is rising fast – especially around communities, schools, and waterways. Nature-Cide's plant-based approach offers a potential alternative that aligns with performance demands while reducing toxicity concerns.
Med-X has earned national and international recognition for providing effective alternatives to conventional pesticides across residential, commercial, and agricultural sectors. Proudly produced in the USA under strict quality standards, Nature-Cide reflects their commitment to sustainable pest management innovation.
With $6.4M in sales in just four years, expanding into 41 international markets, Med-X is getting ready for the next step...
Simpler. Safer. More Effective Pesticides.
Become a Med-X shareholder at $4 per share before their NASDAQ plans unfold.
Option #2: A pure play on "newly public" liquidity and size
ETF: Renaissance IPO ETF (SYM: IPO)
Focuses on the largest, most liquid U.S.-listed newly public companies in a single vehicle.
Renaissance Capital's IPO ETF is explicitly constructed around newly public stocks, aiming to provide exposure to the most liquid U.S.-listed recent IPOs while avoiding overlap with major core indices. Its expense ratio is listed at 0.60%.
This matters because the "newly public" segment often behaves differently than the broad market—especially during issuance waves. When the IPO calendar accelerates and investors chase fresh growth exposure, the cohort can outperform. When risk appetite falls, the cohort can underperform sharply.
Why IPO can fit the thesis
-
Captures the "new listing" cohort effect: A direct way to express IPO-cycle momentum.
-
Reduces single-stock timing risk: No need to guess which debut sticks.
-
Potential SpaceX linkage after listing (if it happens): If SpaceX lists in the U.S. and meets inclusion/liquidity criteria, an IPO-focused index approach could potentially incorporate it over time based on methodology.
Risks to respect
-
Non-diversified construction risk: Some IPO-focused products can become concentrated.
-
Crowded-trade risk: When everyone owns the same "newly public winners," drawdowns can be fast.
-
Event-driven volatility: Lockups, secondary offerings, and post-IPO guidance resets can hit the cohort.
TrendLabs
The Day the AI Trade Breaks
In 2017, I identified Nvidia long before most investors even understood what it was becoming.
Since then, the stock surged as much as 3,852%.
Now I'm seeing something far more important.
I've identified the exact day the AI boom is likely to end.
Click here to see the date.
Are there any other potential IPOs you're following this year? What other sectors of the market are you focusing on in 2026? Hit "reply" to this email and let us know your thoughts!
No comments:
Post a Comment